Skip to Main Content

Smolderen Awarded $1 Million Grant for Critical Limb Ischemia Research

October 13, 2020
by Elisabeth Reitman

Kim Smolderen PhD, co-director of the Vascular Medicine OutcomeS (VAMOS) research program, has been awarded a research grant of over $1M from Janssen Pharmaceuticals and two additional awards from Abbott and W.L. Gore & Associates totaling $1.18M to conduct a prospective observational study on patients with Critical Limb Ischemia (CLI).

She will lead the U.S. multi-center registry called SCOPE-CLI (Shifting Care and Outcomes for Patients with Endangered Limbs – Critical Limb Ischemia) and will be recruiting patients from the Yale New Haven Health System, as well as centers across the US including University of Chicago, UC Davis, UCLA, Baylor College of Medicine, Cleveland Clinic, Emory University, Brown University, Saint Luke’s Mid America Heart Institute, and others.

The VAMOS research team will serve as the coordinating center and co-investigators on the project are Carlos Mena-Hurtado, MD, from Yale University; Mehdi Shishehbor, DO, PhD, from Case Western University/University Hospitals Cleveland; John Spertus, MD, MPH, from Mid America Heart Institute/University of Missouri Kansas City.

The aim of the SCOPE-CLI study is to document the variability in treatment approaches and examine the associations of patient and treatment characteristics with outcomes. The researchers hope to determine whether improved quality of care can be traced to improved health status, fewer amputations, and other adverse limb events. A total of 816 patients will be recruited and followed over the course of 1 year to track patient-centered outcomes, as well as amputations and long-term survival.

To date, there is no systematic disease-specific health status outcomes data for patients with CLI, and studied as a function of patients’ socio-economic status, gender, race, age, or psychosocial background characteristics. The VAMOS research program, co-directed by Drs. Mena-Hurtado and Smolderen, is dedicated to optimizing the quality of care for patients with vascular disease.

“There has been very little clinical evidence to date about the variability in patients’ presentations, their socio-economic and psychosocial characteristics, and associations with their management or their outcomes, said Smolderen. “We hope this will provide us with much needed insights for the field.”

To learn more about the VAMOS research program, visit their website.

Submitted by Elisabeth Reitman on October 13, 2020